ACER — Acer Therapeutics Share Price
Last Trade - 00:00- $35.49m
- $19.59m
- $4.00m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.91 | n/a | n/a | n/a | n/a | 8 | 8.27 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).
Directors
- Stephen Aselage (70)
- Christopher Schelling (45)
- Harry Palmin (51)
- Jefferson Davis (54)
- Donald Joseph (67)
- John Klopp OTH (47)
- Matthew Seibt OTH (50)
- Jason Amello (52)
- John Dunn (69)
- Michelle Griffin (55)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- May 15th, 2018
- Public Since
- September 1st, 2006
- No. of Shareholders
- 90
- No. of Employees
- 20
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 14,310,244
- Address
- One Gateway Center (300 Washington St.), NEWTON, 02458
- Web
- https://acertx.com/
- Phone
- Auditors
- BDO USA, LLP
Latest News for ACER
Upcoming events for ACER
Q3 2021 Acer Therapeutics Inc Earnings Release
Similar to ACER
180 LIFE SCIENCES ORD
NASDAQ Capital Market
9 METERS BIOPHARMA ORD
NASDAQ Capital Market
ABVC BIOPHARMA ORD
NASDAQ Capital Market
ADIAL PHARMACEUTICALS ORD
NASDAQ Capital Market
ADITXT ORD
NASDAQ Capital Market
FAQ
As of Today at 19:54 UTC, shares in Acer Therapeutics are trading at $2.48. This share price information is delayed by 15 minutes.
Shares in Acer Therapeutics last closed at $2.48 and the price had moved by -30.53% over the past 365 days. In terms of relative price strength the Acer Therapeutics share price has underperformed the S&P500 Index by -47.3% over the past year.
The overall consensus recommendation for Acer Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Acer Therapeutics does not currently pay a dividend.
Acer Therapeutics does not currently pay a dividend.
Acer Therapeutics does not currently pay a dividend.
To buy shares in Acer Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.48, shares in Acer Therapeutics had a market capitalisation of $35.49m.
Here are the trading details for Acer Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ACER
Based on an overall assessment of its quality, value and momentum Acer Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Acer Therapeutics is $10.00. That is 303.23% above the last closing price of $2.48.
Analysts covering Acer Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.15 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acer Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -38.04%.
As of the last closing price of $2.48, shares in Acer Therapeutics were trading -15.1% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Acer Therapeutics.
Acer Therapeutics' management team is headed by:
- Stephen Aselage -
- Christopher Schelling -
- Harry Palmin -
- Jefferson Davis -
- Donald Joseph -
- John Klopp - OTH
- Matthew Seibt - OTH
- Jason Amello -
- John Dunn -
- Michelle Griffin -
We do not have data on Acer Therapeutics' shareholders